Literature DB >> 11525214

Changing spectrum of invasive candidiasis and its therapeutic implications.

N Singh1.   

Abstract

Emerging trends in invasive candidiasis are notable for a dramatic increase in infections due to non-albicans Candida species. An increasing number of immunocompromised patients at risk from fungal infections, an overall greater acuity of illness in the hospitalized patients, particularly those in the critical care units, escalating rates of broad-spectrum antibiotic usage, and wide utilization of azoles as prophylaxis have probably contributed towards the changing epidemiology of invasive candidiasis. Given the inherent decreased susceptibility of many of the non-albicans Candida species to currently available antifungal agents, these evolving trends have far-reaching clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11525214     DOI: 10.1111/j.1469-0691.2001.tb00004.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  8 in total

1.  Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection.

Authors:  Phillip H A Lee; Takaaki Ohtake; Mohamed Zaiou; Masamoto Murakami; Jennifer A Rudisill; Kenneth H Lin; Richard L Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

2.  Identification of Candida parapsilosis Sensu Lato in Pediatric Patients and Antifungal Susceptibility Testing.

Authors:  Maria Emilia Cattana; Catiana Dudiuk; Mariana Fernández; Florencia Rojas; Liliana Alegre; Susana Córdoba; Guillermo Garcia-Effron; Gustavo Giusiano
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

3.  Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates.

Authors:  E Roilides; E Farmaki; J Evdoridou; J Dotis; E Hatziioannidis; M Tsivitanidou; E Bibashi; I Filioti; D Sofianou; C Gil-Lamaignere; F-M Mueller; G Kremenopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

Review 4.  Invasive candidiasis in pediatric intensive care units.

Authors:  Sunit Singhi; Akash Deep
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

5.  Candida esophagitis complicated by an esophago-airway fistula: report of a case.

Authors:  Ryu Kanzaki; Masahiko Yano; Ko Takachi; Shingo Ishiguro; Masaaki Motoori; Kentaro Kishi; Isao Miyashiro; Osamu Ishikawa; Shingi Imaoka
Journal:  Surg Today       Date:  2009-11-01       Impact factor: 2.549

6.  Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.

Authors:  A L Colombo; J Perfect; M DiNubile; K Bartizal; M Motyl; P Hicks; R Lupinacci; C Sable; N Kartsonis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-23       Impact factor: 3.267

7.  Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia.

Authors:  David S Krause; John Reinhardt; Jose A Vazquez; Annette Reboli; Beth P Goldstein; Michele Wible; Timothy Henkel
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

8.  Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.

Authors:  Michael A Pfaller; David R Andes; Daniel J Diekema; David L Horn; Annette C Reboli; Coleman Rotstein; Billy Franks; Nkechi E Azie
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.